;PMID: 7078154 ;source_file_1016.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..41] = [t:0..41] ;1)sentence:[e:47..159] = [t:47..159] ;2)section:[e:163..222] = [t:163..222] ;3)sentence:[e:226..492] = [t:226..492] ;4)sentence:[e:493..631] = [t:493..631] ;5)sentence:[e:632..826] = [t:632..826] ;6)sentence:[e:827..999] = [t:827..999] ;7)sentence:[e:1000..1151] = [t:1000..1151] ;8)section:[e:1155..1199] = [t:1155..1199] ;section 0 Span:0..41 ;J Steroid Biochem. 1982 Feb;16(2):157-63. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem) (.:[17..18] .) (CD:[19..23] 1982) (CC:[24..31] Feb;16-LRB-) (CD:[31..32] 2) (-RRB-:[32..33] -RRB-) (CD:[33..37] :157) (::[37..38] -) (CD:[38..40] 63) (.:[40..41] .))) ;sentence 1 Span:47..159 ;Aromatization of 15 alpha and 16 alpha hydroxylated androgens in the human ;placental using [1,2-3H]-substrates. ;[99..108]:substance:"androgens" ;[139..158]:substance:"[1,2-3H]-substrates" (SENT (NP-HLN (NP (NN:[47..60] Aromatization)) (PP (IN:[61..63] of) (NP (NP (ADJP (NML (CD:[64..66] 15) (SYM:[67..72] alpha)) (ADJP-2 (-NONE-:[72..72] *P*))) (NML-1 (-NONE-:[72..72] *P*))) (CC:[73..76] and) (NP (ADJP (NML (CD:[77..79] 16) (SYM:[80..85] alpha)) (ADJP-2 (VBN:[86..98] hydroxylated))) (NML-1 (NNS:[99..108] androgens))))) (PP-LOC (IN:[109..111] in) (NP (DT:[112..115] the) (JJ:[116..121] human) (NN:[123..132] placental))) (S-ADV (NP-SBJ (-NONE-:[132..132] *)) (VP (VBG:[133..138] using) (NP (NNS:[139..158] -LSB-1,2-3H-RSB--substrates)))) (.:[158..159] .))) ;section 2 Span:163..222 ;Cantineau R, Kremers P, De Graeve J, Gielen JE, Lambotte R. (SEC (FRAG (NNP:[163..172] Cantineau) (NNP:[173..175] R,) (NNP:[176..183] Kremers) (NNP:[184..185] P) (,:[185..186] ,) (NNP:[187..189] De) (NNP:[190..196] Graeve) (NNP:[197..199] J,) (NNP:[200..206] Gielen) (NNP:[207..209] JE) (,:[209..210] ,) (NNP:[211..219] Lambotte) (NNP:[220..222] R.))) ;sentence 3 Span:226..492 ;This in vitro study reports data on the aromatization of [1,2-3H]-C19 ;steroids in the human term placenta [androstenedione (III), testosterone ;(IV), 15 alpha-hydroxy-androstenedione (V), 15 alpha-hydroxy-testosterone ;(VI), 16 alpha-hydroxy-androstenedione (VII)]. ;[283..304]:substance:"[1,2-3H]-C19 steroids" ;[334..349]:substance:"androstenedione" ;[351..354]:substance:"III" ;[357..369]:substance:"testosterone" ;[371..373]:substance:"IV" ;[376..409]:substance:"15 alpha-hydroxy-androstenedione" ;[411..412]:substance:"V" ;[415..444]:substance:"15 alpha-hydroxy-testosterone" ;[446..448]:substance:"VI" ;[451..484]:substance:"16 alpha-hydroxy-androstenedione" ;[486..489]:substance:"VII" (SENT (S (NP-SBJ (DT:[226..230] This) (ADJP (FW:[231..233] in) (FW:[234..239] vitro)) (NN:[240..245] study)) (VP (VBZ:[246..253] reports) (NP (NP (NNS:[254..258] data)) (PP (IN:[259..261] on) (NP (NP (DT:[262..265] the) (NN:[266..279] aromatization)) (PP (IN:[280..282] of) (NP (NN:[283..295] -LSB-1,2-3H-RSB--C19) (NNS:[296..304] steroids))) (PP-LOC (IN:[306..308] in) (NP (DT:[309..312] the) (JJ:[313..318] human) (NN:[319..323] term) (NN:[324..332] placenta))) (PRN (-LRB-:[333..334] -LSB-) (NP (NN:[334..349] androstenedione) (PRN (-LRB-:[350..351] -LRB-) (NP (CD:[351..354] III)) (-RRB-:[354..355] -RRB-))) (,:[355..356] ,) (NP (NN:[357..369] testosterone) (PRN (-LRB-:[370..371] -LRB-) (NP (CD:[371..373] IV)) (-RRB-:[373..374] -RRB-))) (,:[374..375] ,) (NP (CD:[376..378] 15) (NN:[380..409] alpha-hydroxy-androstenedione) (PRN (-LRB-:[410..411] -LRB-) (NP (CD:[411..412] V)) (-RRB-:[412..413] -RRB-))) (,:[413..414] ,) (NP (CD:[415..417] 15) (NN:[418..444] alpha-hydroxy-testosterone) (PRN (-LRB-:[445..446] -LRB-) (NP (CD:[446..448] VI)) (-RRB-:[448..449] -RRB-))) (,:[449..450] ,) (NP (CD:[451..453] 16) (NN:[455..484] alpha-hydroxy-androstenedione) (PRN (-LRB-:[485..486] -LRB-) (NP (CD:[486..489] VII)) (-RRB-:[489..490] -RRB-))) (-RRB-:[490..491] -RSB-)))))) (.:[491..492] .))) ;sentence 4 Span:493..631 ;The hydroxylated androgens were microbiologically synthesized from ;commercially radiolabelled [1,2-3H]-androstenedione and testosterone. ;[510..519]:substance:"androgens" ;[589..613]:substance:"[1,2-3H]-androstenedione" ;[618..630]:substance:"testosterone" (SENT (S (NP-SBJ-2 (DT:[493..496] The) (VBN:[497..509] hydroxylated) (NNS:[510..519] androgens)) (VP (VBD:[520..524] were) (ADVP (RB:[526..543] microbiologically)) (VP (VBN:[544..555] synthesized) (NP-2 (-NONE-:[555..555] *)) (PP (IN:[556..560] from) (NP (NP (ADJP-1 (RB:[561..573] commercially) (VBN:[574..587] radiolabelled)) (NN:[589..613] -LSB-1,2-3H-RSB--androstenedione)) (CC:[614..617] and) (NP (ADJP-1 (-NONE-:[617..617] *P*)) (NN:[618..630] testosterone)))))) (.:[630..631] .))) ;sentence 5 Span:632..826 ;Androstenedione and testosterone were good substrates for the human ;placental aromatase (low Km values, high Vmax); they strongly inhibited the ;15 and 16 hydroxylated androgens aromatizations. ;[632..647]:substance:"Androstenedione" ;[652..664]:substance:"testosterone" ;[676..686]:substance:"substrates" ;[711..720]:cyp450:"aromatase" ;[726..728]:quantitative-name:"Km" ;[742..746]:quantitative-name:"Vmax" ;[801..810]:substance:"androgens" (SENT (S (S (NP-SBJ (NN:[632..647] Androstenedione) (CC:[648..651] and) (NN:[652..664] testosterone)) (VP (VBD:[665..669] were) (NP-PRD (NP (JJ:[671..675] good) (NNS:[676..686] substrates)) (PP (IN:[687..690] for) (NP (DT:[691..694] the) (JJ:[695..700] human) (NN:[701..710] placental) (NN:[711..720] aromatase))) (PRN (-LRB-:[721..722] -LRB-) (NP (NP (JJ:[722..725] low) (NN:[726..728] Km) (NNS:[729..735] values)) (,:[735..736] ,) (NP (JJ:[737..741] high) (NN:[742..746] Vmax))) (-RRB-:[746..747] -RRB-))))) (::[747..748] ;) (S (NP-SBJ (PRP:[750..754] they)) (ADVP (RB:[755..763] strongly)) (VP (VBD:[764..773] inhibited) (NP (DT:[774..777] the) (NML (NML (ADJP (CD:[778..780] 15) (ADJP-2 (-NONE-:[780..780] *P*))) (NML-1 (-NONE-:[780..780] *P*))) (CC:[781..784] and) (NML (ADJP (CD:[785..787] 16) (ADJP-2 (VBN:[788..800] hydroxylated))) (NML-1 (NNS:[801..810] androgens) (NNS:[811..825] aromatizations))))))) (.:[825..826] .))) ;sentence 6 Span:827..999 ;On the other hand, these hydroxylated compounds acted as poor substrates and ;were only non-competitive inhibitors of the androstenedione and testosterone ; aromatizations. ;[866..875]:substance:"compounds" ;[890..900]:substance:"substrates" ;[932..942]:substance:"inhibitors" ;[950..965]:substance:"androstenedione" ;[970..982]:substance:"testosterone" (SENT (S (PP (IN:[827..829] On) (NP (DT:[831..834] the) (JJ:[835..840] other) (NN:[841..845] hand))) (,:[845..846] ,) (NP-SBJ (DT:[847..852] these) (VBN:[853..865] hydroxylated) (NNS:[866..875] compounds)) (VP (VP (VBD:[876..881] acted) (PP-CLR (IN:[882..884] as) (NP (JJ:[885..889] poor) (NNS:[890..900] substrates)))) (CC:[901..904] and) (VP (VBD:[905..909] were) (NP-PRD (NP (RB:[911..915] only) (ADJP (AFX:[916..919] non) (HYPH:[919..920] -) (JJ:[920..931] competitive)) (NNS:[932..942] inhibitors)) (PP (IN:[943..945] of) (NP (DT:[946..949] the) (NML (NML (NN:[950..965] androstenedione) (NML-1 (-NONE-:[965..965] *P*))) (CC:[966..969] and) (NML (NN:[970..982] testosterone) (NML-1 (NNS:[984..998] aromatizations))))))))) (.:[998..999] .))) ;sentence 7 Span:1000..1151 ;However, 15 alpha-hydroxy-androstenedione could not be disregarded as a ;potential precursor of 15 alpha-hydroxylated estrogens in the human ;placenta. ;[1009..1041]:substance:"15 alpha-hydroxy-androstenedione" ;[1118..1127]:substance:"estrogens" (SENT (S (ADVP (RB:[1000..1007] However)) (,:[1007..1008] ,) (NP-SBJ-1 (CD:[1009..1011] 15) (NN:[1012..1041] alpha-hydroxy-androstenedione)) (VP (MD:[1042..1047] could) (RB:[1048..1051] not) (VP (VB:[1052..1054] be) (VP (VBN:[1056..1067] disregarded) (NP-1 (-NONE-:[1067..1067] *)) (PP (IN:[1068..1070] as) (NP (NP (DT:[1071..1072] a) (JJ:[1073..1082] potential) (NN:[1083..1092] precursor)) (PP (IN:[1093..1095] of) (NP (ADJP (NML (CD:[1096..1098] 15) (SYM:[1099..1104] alpha)) (HYPH:[1104..1105] -) (VBN:[1105..1117] hydroxylated)) (NNS:[1118..1127] estrogens))) (PP-LOC (IN:[1128..1130] in) (NP (DT:[1131..1134] the) (JJ:[1136..1141] human) (NN:[1142..1150] placenta)))))))) (.:[1150..1151] .))) ;section 8 Span:1155..1199 ;PMID: 7078154 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1155..1159] PMID) (::[1159..1160] :) (CD:[1161..1168] 7078154) (NN:[1169..1170] -LSB-) (NNP:[1170..1176] PubMed) (::[1177..1178] -) (NN:[1179..1186] indexed) (IN:[1187..1190] for) (NNP:[1191..1199] MEDLINE-RSB-)))